"Ivermectin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A mixture of mostly avermectin H2B1a (RN 71827-03-7) with some avermectin H2B1b (RN 70209-81-3), which are macrolides from STREPTOMYCES avermitilis. It binds glutamate-gated chloride channel to cause increased permeability and hyperpolarization of nerve and muscle cells. It also interacts with other CHLORIDE CHANNELS. It is a broad spectrum antiparasitic that is active against microfilariae of ONCHOCERCA VOLVULUS but not the adult form.
| Descriptor ID |
D007559
|
| MeSH Number(s) |
D02.540.576.500.997
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ivermectin".
Below are MeSH descriptors whose meaning is more specific than "Ivermectin".
This graph shows the total number of publications written about "Ivermectin" by people in this website by year, and whether "Ivermectin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 2 | 2 |
| 2017 | 5 | 3 | 8 |
| 2018 | 15 | 7 | 22 |
| 2019 | 6 | 3 | 9 |
| 2020 | 6 | 7 | 13 |
| 2021 | 17 | 3 | 20 |
To return to the timeline, click here.
Below are the most recent publications written about "Ivermectin" by people in Profiles.
-
Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized controlled double-blind, dose-response study in Lagos. QJM. 2022 Jan 05; 114(11):780-788.
-
COVID-19: potential therapeutics for pediatric patients. Pharmacol Rep. 2021 Dec; 73(6):1520-1538.
-
Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. American Journal of Therapeutics, 28, e434-e460, July 2021. Am J Ther. 2021 08 27; 28(5):e573-e576.
-
Comparative study of the interaction of ivermectin with proteins of interest associated with SARS-CoV-2: A computational and biophysical approach. Biophys Chem. 2021 11; 278:106677.
-
Self-prescribed Ivermectin use is associated with a lower rate of seroconversion in health care workers diagnosed with COVID, in a dose-dependent response. Braz J Infect Dis. 2021 Jul-Aug; 25(4):101603.
-
Potential use of ivermectin for the treatment and prophylaxis of SARS-CoV-2 infection. Curr Res Transl Med. 2021 10; 69(4):103309.
-
Pitfalls in Reporting Sample Size Calculation Across Randomized Controlled Trials Involving Ivermectin for the treatment of COVID-19. Am J Ther. 2021 08 06; 28(5):e616-e619.
-
Response to Letter Regarding Article, "Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial". Clin Ther. 2021 09; 43(9):1624-1626.
-
Flawed ivermectin preprint highlights challenges of COVID drug studies. Nature. 2021 08; 596(7871):173-174.
-
Combination Treatment With Remdesivir and Ivermectin Exerts Highly Synergistic and Potent Antiviral Activity Against Murine Coronavirus Infection. Front Cell Infect Microbiol. 2021; 11:700502.